George Emile

Efficacy of Circulating Tumor Cell Count–Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer

François‐Clément Bidard, William Jacot, Nicolas Kiavué et al. · JAMA Oncology · 2020 · 168 citations · Full text

Genomics to select treatment for patients with metastatic breast cancer

Fabrice André, Thomas Filleron, Maud Kamal et al. · Nature · 2022 · 157 citations

Metastatic Breast Cancer, Breast Oncology, Tumor Heterogeneity +9

Impact of body mass index on overall survival in patients with metastatic breast cancer

Khalil Saleh, Matthieu Carton, Véronique Dièras et al. · The Breast · 2020 · 47 citations · Full text

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

Florian Clatot, Anne Perdrix, Ludivine Beaussire et al. · Breast Cancer Research · 2020 · 37 citations · Full text

Comparison of Management and Outcomes in <i>ERBB2</i>-Low vs <i>ERBB2</i>-Zero Metastatic Breast Cancer in France

Ombline de Calbiac, Amélie Lusque, Audrey Mailliez et al. · JAMA Network Open · 2022 · 34 citations · Full text